Under construction – not a live service

Skip to content

Frontlight Research

Trial site

Odense University Hospital

Odense C, DenmarkOdense University Hospital

212running trials
89closed trials
0trials confirmed by the site in the last 60 days
–languages not stated

No trial has been confirmed here yet.

Running trials

Not yet recruiting
Comparison of Neurocognitive Outcome in Two Standard Regimen for Treatment of Low-risk Medulloblastoma
NCT07291102· Phase 3· Source
Not yet recruiting
Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis
NCT07441408· Phase 3· Source
Recruiting
A multicenter, randomized, open-label, blinded-assessor, phase 4 study in patients with early rheumatoid arthritis to compare active conventional therapy versus three biologic treatments, and two de-escalation strategies in patients who respond to treatment.
NCT01491815· Phase 4· Source
Recruiting
A clinical trial to learn about the effects of JFI447 and how it shows up in scans compared to FFG233 in people with solid tumors
2025-523665-24-00· Phase 1· Source
Not yet recruiting
bNAbs and Anti-PD-1 in HIV
NCT07820813· Phase 2· Source
Recruiting
A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D–Mutated Metastatic Pancreatic Ductal Adenocarcinoma (DAWN-303)
2025-525009-18-00· Phase 3· Source
Recruiting
International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)
NCT07476729· Phase 3· Source
Not yet recruiting
Teclistamab in Combination With Pomalidomide Administered in Alternative Fashion in Participants With Relapsed or Refractory Multiple Myeloma.
NCT07757412· Phase 2· Source
Not yet recruiting
A phase II randomised trial investigating the benefit of adjuvant immunotherapy after neoadjuvant chemoimmunotherapy for resectable NSCLC (ADIL)
2025-524439-38-00· Phase 2· Source
Recruiting
A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
NCT07497087· Phase 3· Source
Recruiting
A Phase 1 Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies
2026-525234-39-00· Phase 1· Source
Recruiting
DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy
NCT07544654· Phase 3· Source
Recruiting
A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus
NCT07662109· Phase 3· Source
Not yet recruiting
BEAT Fatigue
2024-519268-41-00· Phase 4· Source
Recruiting
Normethermic Intraperitoneal Chemotherapy - a Novel Concept for Local Treatment of the Elderly and Fragile Women With Advanced Ovarian Cancer?
NCT07733505· Phase 1· Source
Not yet recruiting
The MAYA2 trial
2025-521941-25-00· Phase 2· Source
Recruiting
Crohn’s Head-to-Head Assessing Risankizumab Versus Guselkumab for One Year
2025-521590-13-00· Phase 3· Source
Recruiting
Study of GVV858 as a single agent or in combination with endocrine therapy in patients with HR+/HER2- breast cancer and other advanced solid tumors
2025-521911-38-00· Phase 1/2· Source
Recruiting
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis
NCT07577856· Phase 3· Source
Recruiting
A phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [177Lu]Lu-DFC413 and safety and imaging properties of [68Ga]Ga-NNS309 in patients with solid tumors
2025-521702-18-00· Phase 1· Source
Recruiting
A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)
NCT07570173· Phase 2/3· Source
Recruiting
A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosis
2025-521546-23-00· Phase 3· Source
Recruiting
Inhibiting the Anti-apoptotic Factor, BCL-2, at the Time of ART Initiation to Promote Apoptosis of HIV-infected Cells and Restrict the Seeding of the HIV Reservoir (The INITIATE Study)
NCT07481175· Phase 1· Source
Recruiting
A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)
NCT07489495· Phase 3· Source
Recruiting
LY4268989 (MORF-057) Co-Administered with Mirikizumab in Adults with Moderately to Severely Active Ulcerative Colitis: A Phase 2 Study
2025-522338-30-00· Phase 2· Source
Recruiting
A Randomized, placebo-controlled, double-blinded Phase 2 Trial of Dapagliflozin for Preventing Treatment-associated Cardiotoxicity in Lymphoma
2025-521205-41-00· Phase 2· Source
Recruiting
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
NCT07491445· Phase 3· Source
Recruiting
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
NCT07284849· Phase 3· Source
Not yet recruiting
Neoadjuvant Immunotherapy and Organ-sparing Treatment in Patients With Stage I-III dMMR Colon Cancer
NCT07409844· Phase 2· Source
Recruiting
Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
NCT07223814· Phase 3· Source
Recruiting
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
NCT07318558· Phase 3· Source
Enrolling by invitation
MOdel-Informed Precision Dosing of Ustekinumab and VEdolizumab in Inflammatory Bowel Disease
NCT06788340· Phase 4· Source
Recruiting
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
NCT07216703· Phase 3· Source
Recruiting
A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
NCT06980480· Phase 3· Source
Recruiting
AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
NCT07218809· Phase 3· Source
Recruiting
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
NCT07222800· Phase 3· Source
Recruiting
Study on chemotherapy and experimental drugs in patients with Philadelphia Chromosome positive and ABL-class Philadelphia Chromosome-Like B-cell Acute Lymphoblastic Leukemia
2025-520982-39-00· Phase 3· Source
Recruiting
A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
NCT07227402· Phase 3· Source
Recruiting
PIRTOBRUTINIB AND GLOFITAMAB IN MANTLE CELL LYMPHOMA
2024-512922-27-00· Phase 2· Source
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
NCT07059845· Phase 2· Source
Active, not recruiting
A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)
NCT07076121· Phase 2/3· Source
Recruiting
An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)
NCT07206056· Phase 1/2· Source
Recruiting
Optimized Expansion of the Implanted Transcatheter Aortic Valve
NCT07042529· Source
Recruiting
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
NCT07144280· Phase 3· Source
Recruiting
A study to investigate the effect of AZD6793 in participants with moderate to very severe chronic obstructive pulmonary disease
2025-520473-40-00· Phase 2· Source
Recruiting
A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008)
2024-518296-56-00· Phase 3· Source
Recruiting
Dose Range Finding, Efficacy, and Safety Study of Nebulized CSL787 in Adults With Non-cystic Fibrosis Bronchiectasis (NCFB)
NCT07048262· Phase 2· Source
Recruiting
Methylphenidate in Pediatric Brain Tumor Survivors With Cancer-related Fatigue
NCT06905587· Phase 3· Source
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease
NCT07023289· Phase 2· Source
Active, not recruiting
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine
NCT07018700· Phase 3· Source

Showing 50 of 212.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

Researchers

No researcher is linked here yet.

Closed trials

Active, not recruiting
Study of zoldonrasib in Previously Treated Patients with RAS G12D-Mutant Non-Small Cell Lung Cancer (NSCLC)
2025-521681-10-00· Phase 2· Source
Recruiting
A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)
NCT06747949· Phase 3· Source
Completed
A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy
NCT06797869· Phase 2· Source
Recruiting
Study of IBI3009 in Participants with Unresectable, Metastatic or Extensive-Stage Small Cell Lung Cancer
NCT06613009· Phase 1· Source
Completed
ARETHA: cARdiomems vEriciguaT Heart fAilure (A double-blind randomized placebo-controlled trial of vericiguat in heart failure patients with CardioMEMS™ HF System)
2024-514111-10-00· Phase 4· Source
Recruiting
Effect Camostat for Kidney Protection in Chronic Kidney Disease
NCT06794593· Phase 2· Source
Completed
Identifying Individuals at Risk of Glucocorticoid-Induced Impairment of Bone Disease
NCT06421597· Phase 2· Source
Completed
Identifying Individuals at Risk of Glucocorticoid-Induced Impairment of Bone Disease (RIGID
2023-506949-27-00· Phase 2· Source
Completed
A study to test whether BI 1839100 improves cough in people with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis
2023-510249-79-00· Phase 2· Source
Completed
A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
NCT06335303· Phase 2· Source
Completed
A Dose Range-Finding Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD8630 in Adults With Uncontrolled Asthma at Risk of Exacerbations
NCT06529419· Phase 2· Source
Completed
A study to find how well Dazodalibep works and how safe it is in participants with Sjögren’s Syndrome
2023-503923-24-00· Phase 3· Source
Completed
A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of PLN-74809 (bexotegrast) for the treatment of idiopathic pulmonary fibrosis (BEACON-IPF)
2023-506185-31-00· Phase 2/3· Source
Completed
FDG-PET/CT versus conventional CT for response monitoring in metastatic breast cancer: A pilot study for a randomized clinical trial (MONITOR-PILOT)
2023-506550-20-00· Phase 2/3· Source
Recruiting
A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
NCT06311682· Phase 3· Source
Recruiting
Platform Clinical Study for Conquering Scleroderma
NCT06195072· Phase 2· Source
Completed
A Study of Tobemstomig/RO7247669 Combined with Nab-Paclitaxel Compared with Pembrolizumab Combined with Nab-Paclitaxel in Participants with Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer
2022-502457-34-00· Phase 2· Source
Completed
A Study to Learn How Well the Study Treatment Finerenone Works and How Safe it is in People With Long-term Decrease in the Kidneys' Ability to Work Properly (Chronic Kidney Disease) Together With Type 1 Diabetes
NCT05901831· Phase 3· Source
Completed
GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial Cancer
2022-502453-33-00· Phase 2· Source
Completed
A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity
NCT06104124· Phase 3· Source
Completed
A first-in-human trial of safety and efficacy of GEN3017 in subjects with Hodgkin lymphoma or non-Hodgkin lymphoma
NCT06018129· Phase 1/2· Source
Completed
A Study to Evaluate Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants with Relapsed or Refractory Multiple Myeloma
2023-503689-21-00· Phase 1/2· Source
Completed
Subcutaneous immunoglobulin (HyQvia) against early infections in multiple myeloma: SHIELD
2023-505053-40-00· Phase 2· Source
Completed
A clinical trial to assess the safety and effects of AGMB-129 compared to placebo in patients with fibrostenotic Crohn’s disease.
2022-502789-26-01· Phase 2· Source
Active, not recruiting
A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation
NCT06045806· Phase 3· Source
Terminated
A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion or Subcutaneous (SC) Injection of Budigalimab and/or ABBV-382
NCT06032546· Phase 2· Source
Completed
Phase II, multi‑cohort trial of neoadjuvant and post‑surgery IO102‑IO103 and pembrolizumab in patients with selected resectable tumors
2022-502787-20-00· Phase 2· Source
Completed
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
NCT06065540· Phase 3· Source
Completed
Senolytics to Improve Osteoporosis Therapy
NCT06018467· Phase 2· Source
Active, not recruiting
A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)
NCT06081894· Phase 3· Source
Completed
Phase 2/3 Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
2022-502196-31-00· Phase 2/3· Source
Completed
The RADIAL study: A clinical trial to learn more about the benefits and the acceptability of trials that include technology to centre the trial around the participant, known as decentralised, and hybrid clinical trials compared to standard clinical trials that take place in hospitals or in research centres, in patients with type 2 diabetes mellitus treated with Toujeo®, a drug to help manage blood sugar levels.
2022-500449-26-00· Phase 4· Source
Completed
A Study to Evaluate the Safety of KAND567, in Combination With Carboplatin Therapy, in Women With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT06087289· Phase 1/2· Source
Completed
A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe AD (ROCKET-Horizon)
2022-501538-44-00· Phase 3· Source
Completed
Study of ARO-MMP7 Inhalation Solution in Healthy Participants and Participants With Idiopathic Pulmonary Fibrosis
NCT05537025· Phase 1/2· Source
Completed
A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke
NCT05686070· Phase 3· Source
Active, not recruiting
A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With International Prognostic Scoring System Revised (IPSS-R) Low- or Intermediate-risk Myelodysplastic Syndrome (MDS)
NCT05469737· Phase 2/3· Source
Recruiting
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
NCT05623020· Phase 3· Source
Active, not recruiting
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
NCT05242484· Phase 2· Source
Completed
Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
NCT05255991· Phase 3· Source
Completed
A Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis
NCT05083182· Phase 3· Source
Active, not recruiting
A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
NCT05424822· Phase 1· Source
Active, not recruiting
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease
NCT05242471· Phase 2· Source
Completed
To Evaluate the Safety and Pharmacokinetics of XMAB24306 in Combination with Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma
2024-510644-31-00· Phase 1· Source
Terminated
Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations
NCT05267106· Phase 2· Source
Active, not recruiting
IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)
NCT05155254· Phase 3· Source
Active, not recruiting
A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria
NCT05196035· Phase 3· Source
Completed
Safety and Preliminary Efficacy Assessment of AZD7789 in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
NCT05216835· Phase 1· Source
Completed
HERES trial: Trastuzumab and standard treatment with chemo- and immunotherapy as first line treatment for HER2 positive esophageal squamous cell carcinoma patients
NCT05170256· Phase 2· Source
Completed
A Study to Evaluate the Efficacy and Safety of Astegolimab in Patients With Chronic Obstructive Pulmonary Disease (COPD)
2023-507093-40-00· Phase 2· Source

Showing 50 of 89.

Site data: ClinicalTrials.govUpdated 12 Nov 2026

Report an error

Under construction, not live – Odense University Hospital: trial site – Frontlight Research